Camp4 Therapeutics (NASDAQ: CAMP) posts new Jan 2026 investor presentation

Rhea-AI Filing Summary

CAMP4 Therapeutics Corporation reported that it has updated its corporate investor presentation as of January 2026. The company uses this presentation to provide the investment community with updates and summaries of its business. The refreshed materials are available in the Investors section of its website and have also been furnished as Exhibit 99.1 to this report under Regulation FD.

The company notes that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.

0001736730false00017367302026-01-092026-01-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 9, 2026

CAMP4 THERAPEUTICS CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

001-42365

81-1152476

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

One Kendall Square Building 1400 West, 3rd Floor Cambridge, MA

02139

(Address of principal executive offices)

(Zip Code)

(Registrant’s telephone number, including area code): (617) 651-8867

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

CAMP

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD Disclosure.

From time to time, CAMP4 Therapeutics Corporation (the “Company”) presents and/or distributes slides and presentations to the investment community to provide updates and summaries of its business. On January 9, 2026, the Company updated its corporate presentation, which is available on the “Investors” section of the Company’s website at https://investors.camp4tx.com. This presentation is also furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Corporate presentation, dated January 2026.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			CAMP4 THERAPEUTICS CORPORATION
			By:			/s/ Josh Mandel-Brehm
						Name: Josh Mandel-Brehm
						Title:   President and Chief Executive Officer

Date: January 9, 2026

FAQ

What did CAMP (Camp4 Therapeutics) disclose in this 8-K?

CAMP4 Therapeutics disclosed that it has updated its corporate investor presentation as of January 2026 and made it available to the investment community.

Where can investors find CAMP4 Therapeutics' updated January 2026 presentation?

The updated corporate presentation is available on the Investors section of CAMP4 Therapeutics' website at https://investors.camp4tx.com and is furnished as Exhibit 99.1.

How is the CAMP (CAMP4 Therapeutics) presentation treated under SEC rules?

The information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to Section 18 liability of the Exchange Act and is not incorporated into other filings unless specifically referenced.

Which exhibits are included with this CAMP4 Therapeutics 8-K?

The report includes Exhibit 99.1, the corporate presentation dated January 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

What is the purpose of CAMP4 Therapeutics' corporate presentation for investors?

The company uses its corporate presentation to provide the investment community with updates and summaries of its business, distributed from time to time under Regulation FD.